How many insider trades does FilingIQ track for ELDN?

FilingIQ tracks 27 Form 4 insider transactions for ELDN (Eledon Pharmaceuticals, Inc.), covering filings from Jun 9, 2021 onwards. 4 of those were filed in the last 90 days.

Are ELDN insiders net buyers or net sellers?

Across the full Form 4 history for ELDN, 11 transactions (41%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ELDN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ELDN in?

Eledon Pharmaceuticals, Inc. (ELDN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $244.47M.

ELDN insider trading

NasdaqCM Healthcare

Eledon Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

41% / 0%

Market cap

$244.47M

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Company website: eledon.com

ELDN insider activity at a glance

FilingIQ has scored 27 insider transactions for ELDN since Jun 9, 2021. The most recent filing in our index is dated Jul 31, 2026.

Across the full history, 11 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ELDN insider trades is 61.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ELDN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 967

UNITED THERAPEUTICS Corp

APLS 271

Apellis Pharmaceuticals, Inc.

BLLN 208

BillionToOne, Inc.

KYMR 200

Kymera Therapeutics, Inc.

GH 195

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for ELDN?: FilingIQ tracks 27 Form 4 insider transactions for ELDN (Eledon Pharmaceuticals, Inc.), covering filings from Jun 9, 2021 onwards. 4 of those were filed in the last 90 days.
Are ELDN insiders net buyers or net sellers?: Across the full Form 4 history for ELDN, 11 transactions (41%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ELDN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ELDN in?: Eledon Pharmaceuticals, Inc. (ELDN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $244.47M.

Methodology & sources

Every ELDN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.